Advancements in Acne Management: Pathophysiology and Multimodal Approaches
November 7th 2023Adelaide A. Hebert, MD, FAAD, shares her commentary on advancements in acne management, highlighting advancements in the pathophysiology, benefits of multimodal treatment approaches, and the role of retinoids.
Navigating Skin Aging Across Diverse Tones: Tailored Approaches and Cultural Awareness
October 31st 2023An expert in dermatology discusses the intricacies of addressing anti-aging concerns in patients with diverse skin tones, emphasizing the importance of tailoring management to meet their unique needs, understanding the underlying mechanisms of aging, and appreciating the cultural nuances within patient populations.
Revitalizing Skin Health: Retinoids, OTC Options, and Growth Factors in Aging Prevention
October 31st 2023Dr Kavita Mariwalla, highlights the multifaceted benefits of retinoid-based products in tackling diverse aspects of skin aging, shedding light on the often-underestimated potential of over-the-counter options, while also delving into the role of growth factors, particularly peptides, in skin aging prevention.
Expert Opinion on Strategies for Preventing and Reversing Skin Aging Signs
October 31st 2023Kavita Mariwalla, MD, FAAD, discusses the importance of both preventing and reversing signs of skin aging, highlighting the role of ingredient layering, signaling peptides, and collagen production in maintaining youthful skin.
Navigating the Future of Skincare: Scientific Insights and Advancements
October 17th 2023Hilary Baldwin, MD, offers her insights and hypotheses regarding the future of over-the-counter and pharmaceutical treatments, emphasizing the evolving landscape and the potential role of targeted microbiome-based approaches in the management of acne.
Vitiligo Treatment: Adverse Effects of Ruxolitinib
October 13th 2023Experts review the main adverse effects of ruxolitinib, how to monitor for them in your practice, and the key takeaways for clinicians and payers to know about the 2 phase 3 trials that led to the approval of ruxolitinib in vitiligo.